In terms of incident AEs, fingolimod was the only DMD associated with an increased hazard of ischemic heart disease (aHR, 1.64; 95% CI, 1.10-2.44; crude rate per 1000 person-years [CR], 15.60) and cerebrovascular disease (aHR, 2.04; 95% CI, 1.27-3.30; CR, 10.01). Only alemtuzumab was associated with a significantly higher hazard of chronic kidney disease (aHR, 6.43; 95% CI, 2.60-15.95; <6 cases), while teriflunomide was associated with a significantly higher hazard of chronic liver disease (aHR, 1.94; 95% CI, 1.19-3.18; CR, 11.51) and hyperlipidemia (aHR, 1.61; 95% CiI, 1.07-2.44; CR, 23.92).
Clinical Takeaways
- The research spanned over 25 years, providing a comprehensive understanding of disease-modifying drugs (DMDs) used to treat multiple sclerosis (MS).
- The study assessed seven DMDs: ß-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, and alemtuzumab.
Infection-Related Hospitalizations:
- Current exposure to DMDs was associated with a lower hazard of infection-related hospitalizations, ranging from 42% to 61%, emphasizing a positive impact on immune-related outcomes.
Cardiovascular and Other Risks:
- Fingolimod was linked to an increased hazard of ischemic heart disease and cerebrovascular disease. Alemtuzumab showed a higher risk of chronic kidney disease, while teriflunomide was associated with chronic liver disease and hyperlipidemia.
Hypertension and Mental Health:
- Several DMDs, including alemtuzumab, teriflunomide, fingolimod, and beta-interferon, were associated with an increased hazard of hypertension. Glatiramer acetate and natalizumab increased the hazard of mental health conditions.
Two DMDs were associated with increased risk for thyroid disorders; however, the risk was significantly higher hazard for alemtuzumab (19.42; 95% CI, 9.29-36.51; CR, 36.72) than teriflunomide (2.30; 95% CI, 1.11-4.74; CR, 5.21). The study authors wrote, "Although routine thyroid function testing (before initiation of alemtuzumab and every 3 months thereafter) is recommended, clinicians may wish to consider assessing risk factors for heart diseases, particularly given our observed high crude rate of cardiovascular disorders associated with alemtuzumab (58.92/1,000 person-years) relative to no DMD (25.55)."
A higher hazard for hypertension was observed in alemtuzumab (4.96; 95% CI, 1.78-13.84; <7 cases), teriflunomide (1.76; 95% CI, 1.32-2.37; CR, 42.50), fingolimod (1.73; 95% CI, 1.30-2.31; CR, 31.92), and beta-interferon (1.11; 95% CI, 1.04-1.17; CR, 30.39). Both glatiramer acetate and natalizumab increased the hazard of a mental health condition by 1.16 (95% CI, 1.07-1.26; CR, 85.81) and 1.36 (95% CI, 1.06-1.76; CR, 100.59), respectively.
Glatiramer acetate alone was associated with a lower hazard of hypertension (aHR, 0.87; 95% CI, 0.80-0.95; CR, 25.36) while both glatiramer acetate (aHR, 0.78; 95% CI, 0.65-0.94; CR, 4.61) and dimethyl fumarate (aHR, 0.43; 95% CI, 0.22-0.84; CR, 2.51) were associated with lower hazard of cerebrovascular diseases. No significant differences were observed between individual DMDs and the hazard of autoimmune diseases, cancer, diabetes, or migraine.
REFERENCE
1. Hg HS, Zhu F, Zhao Y, et al. Adverse events associated with disease-modifying drugs for multiple sclerosis: a multiregional population-based study. Neurology. 2024;102(3). doi:10.1212/WNL.000000000000208006